The Latest News

We are pleased to announce that Professor Das Narayandas, BTech, PGDM, PhD, has joined the Advisory Board of Tullis Health Investors. Das Narayandas is the James J. Hill Professor of Business Administration at the Harvard Business School. He is currently the Senior Associate Dean, Chair, Harvard Business Publishing, and Senior Associate Dean, Chair, Executive Education. Das has consulted and/or developed and executed in-house training programs for such companies as Areva, Alghanim Group, GE, Honeywell, IBM, ING, J&J, Mitsubishi Corporation, Linfox, Interbank, Stryker, Merrill Lynch, ThyssenKrupp, Zeiss, Fidelity, Liberty Mutual, 3M, and Microsoft, among other companies, in the areas of B2B marketing, customer satisfaction and loyalty management, strategic marketing, pricing, personal selling and sales management. Das' background includes management experience in sales and marketing that involved field strategic planning, field salesforce management, new product development, channel management and marketing communications. His academic credentials include a Bachelor of Technology degree, a postgraduate diploma in management, and a PhD in management. Jim Tullis, Chairman and Founder, said: “It is exciting for us to have Das join and bring his expertise and wisdom to our Advisory Board. We have known and learned from Das for many years. Many of us have benefited from his outstanding case study sessions. We give him a hearty welcome!”

TULLIS HEALTH INVESTORS INC.

The firm was founded in 1986 by Jim Tullis, a leading health care investment banker and 14-time Institutional Investor All-Star. Under his leadership, the Tullis family of funds has been investing successfully and exclusively in privately held health care companies through several funds for over 30 years. Considered a pioneer in healthcare focused venture and growth capital, the team invests in all major areas of the healthcare industry. US-based, with an office in North Palm Beach, Florida, the firm also has international operations including a presence in Beijing. The team combines extensive operating and clinical experience in the US and globally, with a strong history of successful health care private equity investing.

Investment Approach

Tullis provides equity and equity-related capital to small and emerging health care companies.Tullis focuses on companies that have already established operations or have completed a substantial portion of their development process for new products, technologies and services. Many Tullis companies have generated meaningful revenue and require capital in order to reach value-enhancing milestones in a defined two- to four-year period. Others are research and development stage medical companies which have passed key milestones, but require additional capital to achieve commercial status.